Clinical Trials · NCT00088582
Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Novartis Pharmaceuticals
- Enrollment
- 62
- Start date
- Mar 2004
- Locations
- 5 sites, United States
- Primary endpoint
- Circulating GH- and IGF-1 concentrations measured every 2 weeks